Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for Tanabe Research Laboratories USA Inc., dated June 21, 1996.


--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. .

These include Dow Jones Dow Jones

the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202]

See : Finance
 News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International
UMI United States Minor Outlying Islands (ISO Country code)
UMI University of Miami
UMI Universal Management Infrastructure (IBM) 
 Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-
Published Date:   June 21, 1996


Company Name:     Tanabe Research Laboratories USA Inc.


Address:          4540 Towne Center Court
                  San Diego, Calif.  92121


Main Telephone
 Number:          619/622-7000
 Facsimile:       619/558-0650


Chief Executive
 Officer:         Elias Lazarides, Ph.D.


Chief Financial
 Officer:         Toru Yubiaui


Public Relations
 Contact:         Victoria Smith
 Business number: 619/622-7056
 Home number:     619/624-7494


Industry:         Pharmaceutical -- Drug Discovery


Company description: Tanabe Research Laboratories USA Inc. (TRL TRL

In currencies, this is the abbreviation for the Turkish Lira.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
) is a biopharmaceutical research company located in San Diego. TRL was founded in December 1990 and specializes in the discovery of novel immunoinflammatory therapeutic agents.

TRL scientists have expertise in immunology, cell and molecular biology Cell and Molecular Biology may refer to:
  • Cell biology
  • Molecular biology
, immunopharmacology, peptide and synthetic organic chemistry. Target diseases for research include asthma/allergy, rheumatoid arthritis rheumatoid arthritis

Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course.
 and other autoimmune diseases Autoimmune diseases
A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs.

Mentioned in: Complement Deficiencies, Premature Menopause
. TRL prides itself on its close-knit research culture and emphasis on individual creativity.

TRL is a subsidiary of Tanabe Seiyaku Co. Ltd. of Osaka, Japan. Tanabe Seiyaku was founded in 1687 and is one of the largest and most successful pharmaceutical companies in Japan.

CONTACT: Tanabe Research Laboratories USA Inc., San Diego
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 21, 1996
Words:249
Previous Article:Corporate Profile for Express Systems Inc., dated June 21, 1996.
Next Article:Drilling Results - Devil's Lake Property, La Ronge, Saskatchewan.
Topics:



Related Articles
QBI RECEIVES MILESTONE PAYMENT FROM MITSUBISHI-TOKYO.
L.A. WAKES UP TO WET MORNING.
TEMPERATURES TO RISE BY WEEKEND.
FRIGID STORM LEAVES SOUTHLAND SHIVERING.
Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression.
How to Pay for College.
Tanabe Seiyaku, Maruho Conclude Licensing Agreement for Phosphodiesterase 4 Inhibitor, External Agent for Skin Disease.
Terumo, Tanabe Seiyaku Jointly Launch Amigrand IV Infusion.
Tanabe Seiyaku Launches New Anti-rheumatic.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles